Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases
This dataset contains demographic, clinical, and health-related quality of life (HRQoL) data from 2905 patients including 200 cancer patients after immune checkpoint inhibitor (ICI) cessation and 2705 patients with a wide variety of autoimmune diseases.Within this multicenter, cross-sectional survey...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Data in Brief |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340922008812 |
| _version_ | 1811310852929748992 |
|---|---|
| author | Thomas U. Schulz Sarah Zierold Michael M. Sachse Giulia Pesch Dirk Tomsitz Katharina Schilbach Katharina C. Kähler Lars E. French Lucie Heinzerling |
| author_facet | Thomas U. Schulz Sarah Zierold Michael M. Sachse Giulia Pesch Dirk Tomsitz Katharina Schilbach Katharina C. Kähler Lars E. French Lucie Heinzerling |
| author_sort | Thomas U. Schulz |
| collection | DOAJ |
| description | This dataset contains demographic, clinical, and health-related quality of life (HRQoL) data from 2905 patients including 200 cancer patients after immune checkpoint inhibitor (ICI) cessation and 2705 patients with a wide variety of autoimmune diseases.Within this multicenter, cross-sectional survey study data were collected questionnaire-based in cancer patients (ICI-patients) ≥ 18 years of age who had received at least one dose of ICI with ≥ 12 weeks since ICI discontinuation. Patients with autoimmune diseases (AI-patients) were ≥ 18 years, had at least one autoimmune disease and had never received ICI. ICI-patients were recruited in three skin cancer centers and via support groups. AI-patients were recruited in an outpatient clinic for internal medicine and via support groups.Specific questionnaires for ICI-patients/AI-patients were provided paper-based for patients from outpatient clinics and online for patients from support groups. Both questionnaires contained sections with demographic information, clinical data, and the standardized patient-reported outcome measure EuroQol 5D-5L (EQ-5D-5L) to assess HRQoL. Clinical data focused on autoimmunity and therapy of autoimmunity in (1) ICI-patients referring to particularly persistent immune-related adverse events (persistent irAEs) and in (2) AI-patients referring to respective autoimmune diseases. Additionally, specific items on cancer and cancer therapy were included in ICI-patients, and AI-patients were asked about the presence of acute exacerbations of autoimmune diseases.This dataset contains the raw data for ICI-patients and AI-patients, analyzed data on patient demographics, clinical characteristics and HRQoL scores among ICI-patients with/without persistent irAEs and among AI-patients.The data provide a basis for further investigations within the cohort of ICI-patients after ICI cessation and/or for AI-patients with different autoimmune diseases with regard to HRQoL, autoimmunity and therapy of autoimmunity. |
| first_indexed | 2024-04-13T10:07:35Z |
| format | Article |
| id | doaj.art-78d1eb25ac8243588e14a21f302ea89e |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-04-13T10:07:35Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-78d1eb25ac8243588e14a21f302ea89e2022-12-22T02:51:03ZengElsevierData in Brief2352-34092022-12-0145108676Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseasesThomas U. Schulz0Sarah Zierold1Michael M. Sachse2Giulia Pesch3Dirk Tomsitz4Katharina Schilbach5Katharina C. Kähler6Lars E. French7Lucie Heinzerling8Department of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, GermanyDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, Germany; Side Effect Registry Immuno-Oncology SERIO, http://www.serio-registry.org, Frauenlobstr. 9-11, 80337 Munich, GermanyDepartment of Dermatology, Allergology and Phlebology, Hospital Bremerhaven Reinkenheide, Postbrookstr. 103, 27574 Bremerhaven, GermanyDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, GermanyDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, GermanyMedizinische Klinik und Poliklinik IV, LMU Klinikum, Ziemssenstr. 5, 80336 Munich, GermanyDepartment of Dermatology, University Hospital Schleswig-Holstein, Arnold-Heller-Str. 3, 24105 Kiel, GermanyDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, Germany; Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1295 NW 14th Street, Miami, Florida 33125, USADepartment of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, Germany; Side Effect Registry Immuno-Oncology SERIO, http://www.serio-registry.org, Frauenlobstr. 9-11, 80337 Munich, Germany; Department of Dermatology, University Hospital Erlangen, Ulmenweg 8, 91054 Erlangen, Germany; Corresponding author.This dataset contains demographic, clinical, and health-related quality of life (HRQoL) data from 2905 patients including 200 cancer patients after immune checkpoint inhibitor (ICI) cessation and 2705 patients with a wide variety of autoimmune diseases.Within this multicenter, cross-sectional survey study data were collected questionnaire-based in cancer patients (ICI-patients) ≥ 18 years of age who had received at least one dose of ICI with ≥ 12 weeks since ICI discontinuation. Patients with autoimmune diseases (AI-patients) were ≥ 18 years, had at least one autoimmune disease and had never received ICI. ICI-patients were recruited in three skin cancer centers and via support groups. AI-patients were recruited in an outpatient clinic for internal medicine and via support groups.Specific questionnaires for ICI-patients/AI-patients were provided paper-based for patients from outpatient clinics and online for patients from support groups. Both questionnaires contained sections with demographic information, clinical data, and the standardized patient-reported outcome measure EuroQol 5D-5L (EQ-5D-5L) to assess HRQoL. Clinical data focused on autoimmunity and therapy of autoimmunity in (1) ICI-patients referring to particularly persistent immune-related adverse events (persistent irAEs) and in (2) AI-patients referring to respective autoimmune diseases. Additionally, specific items on cancer and cancer therapy were included in ICI-patients, and AI-patients were asked about the presence of acute exacerbations of autoimmune diseases.This dataset contains the raw data for ICI-patients and AI-patients, analyzed data on patient demographics, clinical characteristics and HRQoL scores among ICI-patients with/without persistent irAEs and among AI-patients.The data provide a basis for further investigations within the cohort of ICI-patients after ICI cessation and/or for AI-patients with different autoimmune diseases with regard to HRQoL, autoimmunity and therapy of autoimmunity.http://www.sciencedirect.com/science/article/pii/S2352340922008812Persistent immune-related adverse events (persistent irAEs)Chronic toxicitiesLong-term sequelaeMelanomahypothyroidismSjogren's syndrome |
| spellingShingle | Thomas U. Schulz Sarah Zierold Michael M. Sachse Giulia Pesch Dirk Tomsitz Katharina Schilbach Katharina C. Kähler Lars E. French Lucie Heinzerling Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases Data in Brief Persistent immune-related adverse events (persistent irAEs) Chronic toxicities Long-term sequelae Melanoma hypothyroidism Sjogren's syndrome |
| title | Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases |
| title_full | Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases |
| title_fullStr | Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases |
| title_full_unstemmed | Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases |
| title_short | Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases |
| title_sort | health related quality of life euroqol 5d 5l in patients with autoimmunity in the context of immunotherapy a large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases |
| topic | Persistent immune-related adverse events (persistent irAEs) Chronic toxicities Long-term sequelae Melanoma hypothyroidism Sjogren's syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S2352340922008812 |
| work_keys_str_mv | AT thomasuschulz healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT sarahzierold healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT michaelmsachse healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT giuliapesch healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT dirktomsitz healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT katharinaschilbach healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT katharinackahler healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT larsefrench healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases AT lucieheinzerling healthrelatedqualityoflifeeuroqol5d5linpatientswithautoimmunityinthecontextofimmunotherapyalargedatasetcomprisingcancerpatientsaftercessationofcheckpointinhibitortherapyandpatientswithautoimmunediseases |